Search

Your search keyword '"Nijziel, Marten R"' showing total 159 results
Start Over Author "Nijziel, Marten R"
159 results on '"Nijziel, Marten R"'

2. Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry

Author

Ekels, Afke, van de Poll-Franse, Lonneke V., Issa, Djamila E., Hoogendoorn, Mels, Nijziel, Marten R., Koster, Adrianus, de Jong, Cornelis N., Achouiti, Ahmed, Thielen, Noortje, Tick, Lidwine W., te Boome, Liane C. J., Bohmer, Lara H., Tiren-Verbeet, Nicolette L., Veldhuis, Gerrit J., de Boer, Fransien, van der Klift, Marjolein, Posthuma, Eduardus F. M., and Oerlemans, Simone

Published
2024
Full Text
View/download PDF

3. Web-Based Self-Management for Patients With Lymphoma: Assessment of the Reach of Intervention of a Randomized Controlled Trial

Author

Arts, Lindy P J, Oerlemans, Simone, Posthuma, Eduardus F M, Issa, Djamila E, Oosterveld, Margriet, van der Griend, René, Nijziel, Marten R, and van de Poll-Franse, Lonneke V

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

BackgroundRandomized controlled trials (RCTs) often provide accurate estimates of the internal validity of an intervention but lack information on external validity (generalizability). We conducted an RCT on the effectiveness of a self-management intervention among patients with lymphoma in a population-based setting. ObjectiveThe objectives of the current study were to describe the proportion of RCT participants compared to all patients invited to participate, and compare sociodemographic and clinical characteristics of RCT participants with all respondents, all patients invited to participate, and all patients selected from the Netherlands Cancer Registry (NCR) to determine the reach of the intervention. An additional objective was to assess differences on RCT outcome variables between RCT and paper respondents. MethodsPatients with lymphoma or chronic lymphocytic leukemia ≥18 years old at diagnosis from 13 hospitals in the Netherlands were selected from the population-based NCR, which routinely collects data on sociodemographic and clinical characteristics. Eligible patients were invited to participate in an RCT and complete a questionnaire. Web-based completion determined RCT enrollment, whereas paper respondents were followed observationally. ResultsA total of 1193 patients were selected from the NCR, 892 (74.77%) of whom were invited to participate in the trial by their hematologist after verifying eligibility. Among those invited, 25.4% (227/892) completed the web-based questionnaire and were enrolled in the RCT. The RCT participants were younger and there was a higher proportion of men than nonparticipants (P

Published
2020
Full Text
View/download PDF

5. Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study

Author

Hamulyák, Eva N., Wiegers, Hanke M.G., Scheres, Luuk J.J., Hutten, Barbara A., de Lange, Maria E., Timmermans, Anne, Westerweel, Peter E., Nijziel, Marten R., Kruip, Marieke J.H.A., ten Wolde, Marije, Ypma, Paula F., Klok, Frederikus A., Nieuwenhuizen, Laurens, van Wissen, Sanne, Hovens, Marcel M.C., Faber, Laura M., Kamphuisen, Pieter W., Büller, Harry R., and Middeldorp, Saskia

Published
2021
Full Text
View/download PDF

6. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Cancer, Verpleegkundig specialisten & PA's, MS Hematologie, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., te Boome, LCJ, Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Published
2024

7. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., Schaapveld, Michael, Neppelenbroek, Suzanne I.M., Geurts, Yvonne M., Aleman, Berthe M.P., Lugtenburg, Pieternella J., Rademakers, Saskia E., De Weijer, Roel J., Schippers, Maaike G.A., Ta, Bastiaan D.P., Plattel, Wouter J., Zijlstra, Josée M., Van Der Maazen, Richard W.M., Nijziel, Marten R., Ong, Francisca, Schimmel, Erik C., Posthuma, Eduardus F.M., Kersten, Marie José, Böhmer, Lara H., Muller, Karin, Koene, Harry R., Te Boome, Liane C.J., Bilgin, Yavuz M., De Jongh, Eva, Janus, Cécile P.M., Van Leeuwen, Flora E., and Schaapveld, Michael

Abstract

PURPOSEFemale Hodgkin lymphoma (HL) survivors treated with chest radiotherapy (RT) at a young age have a strongly increased risk of breast cancer (BC). Studies in childhood cancer survivors have shown that doxorubicin exposure may also increase BC risk. Although doxorubicin is the cornerstone of HL chemotherapy, the association between doxorubicin and BC risk has not been examined in HL survivors treated at adult ages.METHODSWe assessed BC risk in a cohort of 1,964 female 5-year HL survivors, treated at age 15-50 years in 20 Dutch hospitals between 1975 and 2008. We calculated standardized incidence ratios, absolute excess risks, and cumulative incidences. Doxorubicin exposure was analyzed using multivariable Cox regression analyses.RESULTSAfter a median follow-up of 21.6 years (IQR, 15.8-27.1 years), 252 women had developed invasive BC or ductal carcinoma in situ. The 30-year cumulative incidence was 20.8% (95% CI, 18.2 to 23.4). Survivors treated with a cumulative doxorubicin dose of >200 mg/m2 had a 1.5-fold increased BC risk (95% CI, 1.08 to 2.1), compared with survivors not treated with doxorubicin. BC risk increased 1.18-fold (95% CI, 1.05 to 1.32) per additional 100 mg/m2 doxorubicin (Ptrend =.004). The risk increase associated with doxorubicin (yes v no) was not modified by age at first treatment (hazard ratio [HR]age <21 years, 1.5 [95% CI, 0.9 to 2.6]; HRage ≥21 years, 1.3 [95% CI, 0.9 to 1.9) or chest RT (HRwithout mantle/axillary field RT, 1.9 [95% CI, 1.06 to 3.3]; HRwith mantle/axillary field RT, 1.2 [95% CI, 0.8 to 1.8]).CONCLUSIONThis study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.

Published
2024

8. Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M., additional, Aleman, Berthe M.P., additional, Lugtenburg, Pieternella J., additional, Rademakers, Saskia E., additional, de Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, de Jongh, Eva, additional, Janus, Cécile P.M., additional, van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2024
Full Text
View/download PDF

11. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, primary, Krul, Inge M., additional, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Rademakers, Saskia E., additional, Roesink, Judith M., additional, Nijziel, Marten R., additional, Bilgin, Yavuz M., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

12. The course of self-perceived cognitive functioning among patients with lymphoma and the co-occurrence with fatigue and psychological distress

Author

Ekels, Afke, primary, Oerlemans, Simone, additional, Schagen, Sanne B., additional, Issa, Djamila E., additional, Thielen, Noortje, additional, Nijziel, Marten R., additional, Poel, Marjolein W.M., additional, Arts, Lindy P.J., additional, Posthuma, Eduardus F.M., additional, and Poll-Franse, Lonneke V., additional

Published
2023
Full Text
View/download PDF

13. Risk of male breast cancer after Hodgkin lymphoma

Author

van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

14. Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Author

Levin, Mark-David, primary, Kersting, Sabina, additional, Dubois, Julie M.N., additional, Norden, Yvette, additional, Dobber, Johan A, additional, Jauw, Yvonne W.S., additional, Kevie-Kersemaekers, Anne-Marie van der, additional, Mellink, Clemens, additional, Heer, Koen de, additional, Burg, Leonie van der, additional, Raa, Doreen Te, additional, Boer, Fransien de, additional, Droogendijk, Jolanda, additional, Idink, Cecile, additional, Nijziel, Marten R., additional, Tick, Lidwine W., additional, Ludwig, Inge, additional, Silbermann, Matthijs, additional, Beeker, Aart, additional, Bellido, Mar, additional, Evers, Ludo M., additional, Zwezerijnen, Gerben JC, additional, Niemann, Carsten U, additional, and Kater, Arnon P., additional

Published
2022
Full Text
View/download PDF

15. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma

Author

Krul, Inge M., primary, Boekel, Naomi B., additional, Kramer, Iris, additional, Janus, Cécile P. M., additional, Krol, Augustinus D. G., additional, Nijziel, Marten R., additional, Zijlstra, Josée M., additional, van der Maazen, Richard W. M., additional, Roesink, Judith M., additional, Jacobse, Judy N., additional, Schaapveld, Michael, additional, Schmidt, Marjanka K., additional, Opstal‐van Winden, Annemieke W. J., additional, Sonke, Gabe S., additional, Russell, Nicola S., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2022
Full Text
View/download PDF

16. T064: Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M.G., additional, Aleman, Berthe M. P., additional, Janus, Cécile P.M., additional, Lugtenburg, Pieternella J., additional, Rademaker, Saskia E., additional, De Weijer, Roel J., additional, Schippers, Maaike G.A., additional, Ta, Bastiaan D.P., additional, Plattel, Wouter J., additional, Zijlstra, Josée. M., additional, Van Der Maazen, Richard W.M., additional, Nijziel, Marten R., additional, Ong, Francisca, additional, Schimmel, Erik C., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Böhmer, Lara H., additional, Muller, Karin, additional, Koene, Harry R., additional, Te Boome, Liane C.J., additional, Bilgin, Yavuz M., additional, De Jongh, Eva, additional, Van Leeuwen, Flora E., additional, and Schaapveld, Michael, additional

Published
2022
Full Text
View/download PDF

17. Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma

Author

MS Radiotherapie, Cancer, Krul, Inge M, Boekel, Naomi B, Kramer, Iris, Janus, Cécile P M, Krol, Augustinus D G, Nijziel, Marten R, Zijlstra, Josée M, van der Maazen, Richard W M, Roesink, Judith M, Jacobse, Judy N, Schaapveld, Michael, Schmidt, Marjanka K, Opstal-van Winden, Annemieke W J, Sonke, Gabe S, Russell, Nicola S, Aleman, Berthe M P, van Leeuwen, Flora E, MS Radiotherapie, Cancer, Krul, Inge M, Boekel, Naomi B, Kramer, Iris, Janus, Cécile P M, Krol, Augustinus D G, Nijziel, Marten R, Zijlstra, Josée M, van der Maazen, Richard W M, Roesink, Judith M, Jacobse, Judy N, Schaapveld, Michael, Schmidt, Marjanka K, Opstal-van Winden, Annemieke W J, Sonke, Gabe S, Russell, Nicola S, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2022

19. Persistent symptoms of fatigue, neuropathy and role‐functioning impairment among indolent non‐Hodgkin lymphoma survivors: A longitudinal PROFILES registry study

Author

Ekels, Afke, primary, Poll‐Franse, Lonneke V., additional, Posthuma, Eduardus F. M., additional, Kieffer, Jacobien, additional, Issa, Djamila E., additional, Koster, Adrianus, additional, Nijziel, Marten R., additional, Pruijt, Johannes H. F. M., additional, Stevens, Wendy B. C., additional, Tick, Lidwine W., additional, and Oerlemans, Simone, additional

Published
2022
Full Text
View/download PDF

23. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Author

Raa, Doreen G. Te, van der Straten, Lina, van Gelder, Michel, Kersting, Sabina, Levin, Mark-David, Mous, Rogier, van der Straaten, Hanneke M., Nijziel, Marten R., van der Spek, Ellen, Posthuma, Eduardus F. M, Visser, Hein P.J, van der Klift, Marjolein, de Heer, Koen, Bellido, Mar, Doorduijn, Jeanette K., Bruns, Anke H.W, Raijmakers, Reinier A. P, and Kater, Arnon P.

Subjects
CHRONIC lymphocytic leukemia, DIAGNOSIS
Abstract

Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function

Author

Tullemans, Bibian M.E., primary, Karel, Mieke F.A., additional, Léopold, Valentine, additional, ten Brink, Marieke S., additional, Baaten, Constance C.F.M.J., additional, Maas, Sanne L., additional, de Vos, Alex F., additional, Eble, Johannes A., additional, Nijziel, Marten R., additional, van der Vorst, Emiel P.C., additional, Cosemans, Judith M.E.M., additional, Heemskerk, Johan W.M., additional, Claushuis, Theodora A.M., additional, and Kuijpers, Marijke J.E., additional

Published
2021
Full Text
View/download PDF

25. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., van Leeuwen, Flora E., de Vries, Simone, Schaapveld, Michael, Janus, Cécile P.M., Daniëls, Laurien A., Petersen, Eefke J., van der Maazen, Richard W.M., Zijlstra, Josée M., Beijert, Max, Nijziel, Marten R., Verschueren, Karijn M.S., Kremer, Leontien C.M., van Eggermond, Anna M., Lugtenburg, Pieternella J., Krol, Augustinus D.G., Roesink, Judith M., Plattel, Wouter J., van Spronsen, Dick Johan, van Imhoff, Gustaaf W., de Boer, Jan Paul, Aleman, Berthe M.P., and van Leeuwen, Flora E.

Abstract

BACKGROUND: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients. METHODS: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated. RESULTS: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02). CONCLUSIONS: Compared with the general population, HL survivors have a su

Published
2021

26. Long-term cause-specific mortality in hodgkin lymphoma patients

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, van Leeuwen, Flora E, MS Hematologie, Regenerative Medicine and Stem Cells, Cancer, MS Radiotherapie, de Vries, Simone, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, van der Maazen, Richard W M, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, van Eggermond, Anna M, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, van Spronsen, Dick Johan, van Imhoff, Gustaaf W, de Boer, Jan Paul, Aleman, Berthe M P, and van Leeuwen, Flora E

Published
2021

29. Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.

Author

Geurts, Yvonne M., primary, Neppelenbroek, Suzanne I.M., additional, So-Osman, Cynthia, additional, Vermaat, Joost S.P., additional, van Spronsen, Dick Johan, additional, Plattel, Wouter J., additional, de Weijer, Roel J., additional, Verschueren, Karijn M.S., additional, Zijlstra, Josée M., additional, Koene, Harry R., additional, Nijziel, Marten R., additional, Schimmel, Erik C., additional, Böhmer, Lara H., additional, Ong, Francisca, additional, Visser, Hein, additional, van Kampen, Daphne, additional, Kersten, Marie José, additional, Aleman, Berthe M.P., additional, Van Leeuwen, Flora, additional, and Schaapveld, Michael, additional

Published
2021
Full Text
View/download PDF

30. Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors.

Author

Neppelenbroek, Suzanne I.M., primary, Geurts, Yvonne M., additional, Aleman, Berthe M.P., additional, Janus, Cecile P.M., additional, Rademakers, Saskia E, additional, de Weijer, Roel J., additional, Van Der Maazen, Richard W.M., additional, Zijlstra, Josée M., additional, Beijert, Max, additional, Verschueren, Karijn M.S., additional, Ta, Bastiaan, additional, Nijziel, Marten R., additional, Posthuma, Eduardus F.M., additional, Kersten, Marie José, additional, Muller, Karin, additional, te Boome, Liane, additional, Bilgin, Yavuz, additional, de Jongh, Eva, additional, Schaapveld, Michael, additional, and Van Leeuwen, Flora, additional

Published
2021
Full Text
View/download PDF

32. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients

Author

de Vries, Simone, primary, Schaapveld, Michael, additional, Janus, Cécile P M, additional, Daniëls, Laurien A, additional, Petersen, Eefke J, additional, van der Maazen, Richard W M, additional, Zijlstra, Josée M, additional, Beijert, Max, additional, Nijziel, Marten R, additional, Verschueren, Karijn M S, additional, Kremer, Leontien C M, additional, van Eggermond, Anna M, additional, Lugtenburg, Pieternella J, additional, Krol, Augustinus D G, additional, Roesink, Judith M, additional, Plattel, Wouter J, additional, van Spronsen, Dick Johan, additional, van Imhoff, Gustaaf W, additional, de Boer, Jan Paul, additional, Aleman, Berthe M P, additional, and van Leeuwen, Flora E, additional

Published
2020
Full Text
View/download PDF

33. Severe arterial thromboembolism in patients with Covid-19

Author

Lameijer, Joost R.C., primary, van Houte, Joris, additional, van Berckel, Marijn M.G., additional, Canta, Leo R., additional, Yo, Lonneke S.F., additional, Nijziel, Marten R., additional, Krietemeijer, G.M., additional, Troquay, Stephanie A.M., additional, Buise, Marc P., additional, and Hendriks, Joris, additional

Published
2020
Full Text
View/download PDF

34. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Author

Herishanu, Yair, primary, Shaulov, Adir, additional, Fineman, Riva, additional, Bašić‐Kinda, Sandra, additional, Aviv, Ariel, additional, Wasik‐Szczepanek, Ewa, additional, Jaksic, Ozren, additional, Zdrenghea, Mihnea, additional, Greenbaum, Uri, additional, Mandac, Inga, additional, Simkovic, Martin, additional, Morawska, Marta, additional, Benjamini, Ohad, additional, Spacek, Martin, additional, Nemets, Anatoly, additional, Bairey, Osnat, additional, Trentin, Livio, additional, Ruchlemer, Rosa, additional, Laurenti, Luca, additional, Stanca Ciocan, Oana, additional, Doubek, Michael, additional, Shvidel, Lev, additional, Dali, Nagib, additional, Mirás, Fátima, additional, De Meûter, Anne, additional, Dimou, Maria, additional, Mauro, Francesca R., additional, Coscia, Marta, additional, Bumbea, Horia, additional, Szász, Róbert, additional, Tadmor, Tamar, additional, Gutwein, Odit, additional, Gentile, Massimo, additional, Scarfò, Lydia, additional, Tedeschi, Alessandra, additional, Sportoletti, Paolo, additional, Gimeno Vázquez, Eva, additional, Marquet, Juan, additional, Assouline, Sarit, additional, Papaioannou, Maria, additional, Braester, Andrei, additional, Levato, Luciano, additional, Gregor, Michael, additional, Rigolin, Gian M., additional, Loscertales, Javier, additional, Medina Perez, Angeles, additional, Nijziel, Marten R., additional, Popov, Viola M., additional, Collado, Rosa, additional, Slavutsky, Irma, additional, Itchaki, Gilad, additional, Ringelstein, Shimrit, additional, Goldschmidt, Neta, additional, Perry, Chava, additional, Levi, Shai, additional, Polliack, Aaron, additional, and Ghia, Paolo, additional

Published
2020
Full Text
View/download PDF

35. Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis

Author

Saes, Joline L, Simons, Annet, de Munnik, Sonja A, Nijziel, Marten R, Blijlevens, Nicole M A, Jongmans, Marjolijn C, van der Reijden, Bert A, Smit, Yolba, Brons, Paul P, van Heerde, Waander L, Schols, Saskia E M, Saes, Joline L, Simons, Annet, de Munnik, Sonja A, Nijziel, Marten R, Blijlevens, Nicole M A, Jongmans, Marjolijn C, van der Reijden, Bert A, Smit, Yolba, Brons, Paul P, van Heerde, Waander L, and Schols, Saskia E M

Published
2019

36. The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Bury, Didi, Ter Heine, Rob, van de Garde, Ewoudt M W, Nijziel, Marten R, Grouls, Rene J, Deenen, Maarten J, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Bury, Didi, Ter Heine, Rob, van de Garde, Ewoudt M W, Nijziel, Marten R, Grouls, Rene J, and Deenen, Maarten J

Published
2019

37. Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis

Author

Genetica Klinische Genetica, Cancer, Saes, Joline L, Simons, Annet, de Munnik, Sonja A, Nijziel, Marten R, Blijlevens, Nicole M A, Jongmans, Marjolijn C, van der Reijden, Bert A, Smit, Yolba, Brons, Paul P, van Heerde, Waander L, Schols, Saskia E M, Genetica Klinische Genetica, Cancer, Saes, Joline L, Simons, Annet, de Munnik, Sonja A, Nijziel, Marten R, Blijlevens, Nicole M A, Jongmans, Marjolijn C, van der Reijden, Bert A, Smit, Yolba, Brons, Paul P, van Heerde, Waander L, and Schols, Saskia E M

Published
2019

39. Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

Author

Vries, Simone de, Schaapveld, Michael, Janus, Cécile P M, Daniëls, Laurien A, Petersen, Eefke J, Maazen, Richard W M van der, Zijlstra, Josée M, Beijert, Max, Nijziel, Marten R, Verschueren, Karijn M S, Kremer, Leontien C M, Eggermond, Anna M van, Lugtenburg, Pieternella J, Krol, Augustinus D G, Roesink, Judith M, Plattel, Wouter J, Spronsen, Dick Johan van, Imhoff, Gustaaf W van, Boer, Jan Paul de, and Aleman, Berthe M P

Subjects
HODGKIN'S disease, CARDIOVASCULAR disease related mortality, DEATH rate, MORTALITY, SPLEEN, CAUSES of death, RESEARCH, RESEARCH methodology, CANCER relapse, EVALUATION research, COMPARATIVE studies, SECONDARY primary cancer, LONGITUDINAL method
Abstract

Background: Few studies have examined the impact of treatment-related morbidity on long-term, cause-specific mortality in Hodgkin lymphoma (HL) patients.Methods: This multicenter cohort included 4919 HL patients, treated before age 51 years between 1965 and 2000, with a median follow-up of 20.2 years. Standardized mortality ratios, absolute excess mortality (AEM) per 10 000 person-years, and cause-specific cumulative mortality by stage and primary treatment, accounting for competing risks, were calculated.Results: HL patients experienced a 5.1-fold (AEM = 123 excess deaths per 10 000 person-years) higher risk of death due to causes other than HL. This risk remained increased in 40-year survivors (standardized mortality ratio = 5.2, 95% confidence interval [CI] = 4.2 to 6.5, AEM = 619). At age 54 years, HL survivors experienced similar cumulative mortality (20.0%) from causes other than HL to 71-year-old individuals from the general population. Whereas HL mortality statistically significantly decreased over the calendar period (P < .001), solid tumor mortality did not change in the most recent treatment era. Patients treated in 1989-2000 had lower 25-year cardiovascular disease mortality than patients treated in 1965-1976 (4.3% vs 5.7%; subdistribution hazard ratio = 0.65, 95% CI = 0.46 to 0.93). Infectious disease mortality was not only increased after splenectomy but also after spleen irradiation (hazard ratio = 2.81, 95% CI = 1.55 to 5.07). For stage I-II, primary treatment with chemotherapy (CT) alone was associated with statistically significantly higher HL mortality (P < .001 for CT vs radiotherapy [RT]; P = .04 for CT vs RT+CT) but lower 30-year mortality from causes other than HL (15.8%, 95% CI = 9.7% to 23.3%) compared with RT alone (36.9%, 95% CI = 34.0% to 39.8%, P = .001) and RT and CT combined (29.8%, 95% CI = 26.8% to 32.9%, P = .02).Conclusions: Compared with the general population, HL survivors have a substantially reduced life expectancy. Optimal selection of patients for primary CT is crucial, weighing risks of HL relapse and long-term toxicity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Author

Herishanu, Yair, primary, Shaulov, Adir, additional, Fineman, Riva, additional, Bašić-Kinda, Sandra, additional, Aviv, Ariel, additional, Wasik-Szczepanek, Ewa, additional, Jaksic, Ozren, additional, Zdrenghea, Mihnea, additional, Greenbaum, Uri, additional, Mandac, Inga, additional, Simkovic, Martin, additional, Morawska, Marta, additional, Benjamini, Ohad, additional, Spacek, Martin, additional, Nemets, Anatoly, additional, Bairey, Osnat, additional, Visentin, Andrea, additional, Ruchlemer, Rosa, additional, Laurenti, Luca, additional, Stanca Ciocan, Oana, additional, Doubek, Michael, additional, Shvidel, Lev, additional, Deli, Nagib, additional, Miras Calvo, Fatima, additional, De Meûter, Anne, additional, Dimou, Maria, additional, Mauro, Francesca Romana, additional, Coscia, Marta, additional, Bumbea, Horia, additional, Róbert, Szász, additional, Tadmor, Tamar, additional, Gutwein, Odit, additional, Gentile, Massimo, additional, Scarfo, Lydia, additional, Tedeschi, Alessandra, additional, Sportoletti, Paolo, additional, Gimeno Vázquez, Eva, additional, Marquet Palomanes, Juan, additional, Assouline, Sarit, additional, Papaioannou, Maria, additional, Breaster, Andrei, additional, Levato, Luciano, additional, Gregor, Michael, additional, Rigolin, Gian Matteo, additional, Loscertales, Javier, additional, Medina Perez, Angeles, additional, Nijziel, Marten R., additional, Popov, Viola Maria, additional, Collado, Rosa, additional, Slavutsky, Irma, additional, Levi, Shai, additional, Polliack, Aaron, additional, and Ghia, Paolo, additional

Published
2019
Full Text
View/download PDF

43. Whole exome sequencing in the diagnostic workup of patients with a bleeding diathesis.

Author

Blijlevens, Nicole M. A., Smit, Yolba, Saes, Joline L., Schols, Saskia E. M., van Heerde, Waander L., Brons, Paul P., Simons, Annet, de Munnik, Sonja A., Jongmans, Marjolijn C., Nijziel, Marten R., and van der Reijden, Bert A.

Abstract

Introduction: Bleeding assessment tools and laboratory phenotyping often remain inconclusive in patients with a haemorrhagic diathesis. Aim: To describe the phenotype and genetic profile of patients with a bleeding tendency. Methods: Whole exome sequencing (WES) was incorporated in the routine diagnostic pathway of patients with thrombocytopenia (n = 17), platelet function disorders (n = 19) and an unexplained bleeding tendency (n = 51). The analysis of a panel of 126 OMIM (Online Mendelian Inheritance in Man) genes involved in thrombosis and haemostasis was conducted, and if negative, further exome‐wide analysis was performed if informed consent given. Results: Eighteen variants were detected in 15 patients from a total of 87 patients (17%). Causative variants were observed in MYH9 (two cases), SLFN14, P2RY12 and GP9. In addition, one case was considered solved due to combined carriership of F7 and F13A1 variants and one with combined carriership of F2, F8 and VWF, all variants related to secondary haemostasis protein aberrations. Two variants of uncertain significance (VUS) were found in two primary haemostasis genes: GFI1B and VWF. Eight patients were carriers of autosomal recessive disorders. Exome‐wide analysis was performed in 54 cases and identified three variants in candidate genes. Conclusion: Based on our findings, we conclude that performing WES at the end of the diagnostic trajectory can be of additive value to explain the complete bleeding phenotype in patients without a definite diagnosis after conventional laboratory tests. Discovery of combinations of (novel) genes that predispose to bleeding will increase the diagnostic yield in patients with an unexplained bleeding diathesis. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

44. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Abstract

•Male survivors of HL treated with chest radiotherapy have an increased risk of developing BC compared with the general population.•Although the occurrence of male BC is an uncommon event, clinicians should be alert to BC symptoms in male survivors of HL.

Published
2024
Full Text
View/download PDF

46. Iron refractory iron deficiency anemia : a heterogeneous disease that is not always iron refractory

Author

Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, Swinkels, Dorine W, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, and Swinkels, Dorine W

Published
2016

47. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory

Author

MS Dermatologie/Allergologie, Haematologie patientenzorg, Child Health, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, Swinkels, Dorine W, MS Dermatologie/Allergologie, Haematologie patientenzorg, Child Health, Donker, Albertine E, Schaap, Charlotte C M, Novotny, Vera M J, Smeets, Roel, Peters, Tessa M A, van den Heuvel, Bert L P, Raphael, Martine F, Rijneveld, Anita W, Appel, Inge M, Vlot, Andre J, Versluijs, A Birgitta, van Gelder, Michel, Granzen, Bernd, Janssen, Mirian C H, Rennings, Alexander J M, van de Veerdonk, Frank L, Brons, Paul P T, Bakkeren, Dirk L, Nijziel, Marten R, Vlasveld, L Thom, and Swinkels, Dorine W

Published
2016

48. Two Cases of Q-Fever in Hairy Cell Leukemia

Author

Ammatuna, Emanuele, Iannitto, Emilio, Tick, Lidwine W., Arents, Nicolaas L. A., Kuijper, Philip H., and Nijziel, Marten R.

Subjects
Article Subject
Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder accounting for about 2% of all leukemias. The clinical course is indolent, however HCL patients are particularly susceptible to infections. Here we report two cases of Q-fever as first manifestation of disease in two patients affected by HCL. Both patients described in this report showed an unusually sluggish clinical response to the antibiotic treatment with ciprofloxacin probably because of the marked immunodeficiency. However, treatment of HCL with cladribine administered soon after the resolution of QF pneumonitis was uneventful and led to a complete remission in both cases. Most probably the association of Coxiella burnetii (CB) infection and HCL that we observed in two patients is due to chance. However, a hairy cell resembling transformation of freshly isolated human peripheral blood lymphocytes upon CB has been showed. We think that the possibility of CB infection in febrile HCL patient should be always taken in mind, especially in endemic areas. In addition the potential for such infections to become chronic in HCL patients should not be overlooked and the reporting of further cases should be encouraged.

Published
2014
Full Text
View/download PDF

49. Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory

Author

Donker, Albertine E., primary, Schaap, Charlotte C.M., additional, Novotny, Vera M. J., additional, Smeets, Roel, additional, Peters, Tessa M. A., additional, van den Heuvel, Bert L. P., additional, Raphael, Martine F., additional, Rijneveld, Anita W., additional, Appel, Inge M., additional, Vlot, Andre J., additional, Versluijs, A. Birgitta, additional, van Gelder, Michel, additional, Granzen, Bernd, additional, Janssen, Mirian C.H., additional, Rennings, Alexander J.M., additional, van de Veerdonk, Frank L., additional, Brons, Paul P.T., additional, Bakkeren, Dirk L., additional, Nijziel, Marten R., additional, Vlasveld, L. Thom, additional, and Swinkels, Dorine W., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results